vs
Pacira BioSciences, Inc.（PCRX）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
ROYAL GOLD INC的季度营收约是Pacira BioSciences, Inc.的2.1倍（$375.3M vs $177.4M），ROYAL GOLD INC净利率更高（24.9% vs 1.6%，领先23.3%），ROYAL GOLD INC同比增速更快（85.3% vs 5.0%），过去两年ROYAL GOLD INC的营收复合增速更高（58.8% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
PCRX vs RGLD — 直观对比
营收规模更大
RGLD
是对方的2.1倍
$177.4M
营收增速更快
RGLD
高出80.3%
5.0%
净利率更高
RGLD
高出23.3%
1.6%
两年增速更快
RGLD
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $375.3M |
| 净利润 | $2.9M | $93.6M |
| 毛利率 | — | 64.6% |
| 营业利润率 | 3.9% | 56.2% |
| 净利率 | 1.6% | 24.9% |
| 营收同比 | 5.0% | 85.3% |
| 净利润同比 | — | -12.8% |
| 每股收益（稀释后） | $0.07 | $1.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXRGLD
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $375.3M | ||
| Q3 25 | $179.5M | $252.1M | ||
| Q2 25 | $181.1M | $209.6M | ||
| Q1 25 | $168.9M | $193.4M | ||
| Q4 24 | $187.3M | $202.6M | ||
| Q3 24 | $168.6M | $193.8M | ||
| Q2 24 | $178.0M | $174.1M |
净利润PCRXRGLD
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $93.6M | ||
| Q3 25 | $5.4M | $126.8M | ||
| Q2 25 | $-4.8M | $132.3M | ||
| Q1 25 | $4.8M | $113.5M | ||
| Q4 24 | — | $107.4M | ||
| Q3 24 | $-143.5M | $96.2M | ||
| Q2 24 | $18.9M | $81.2M |
毛利率PCRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 64.6% | ||
| Q3 25 | 80.9% | 73.6% | ||
| Q2 25 | 77.4% | 72.6% | ||
| Q1 25 | 79.7% | 69.4% | ||
| Q4 24 | 78.7% | 70.3% | ||
| Q3 24 | 76.9% | 66.6% | ||
| Q2 24 | 75.1% | 64.7% |
营业利润率PCRXRGLD
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 56.2% | ||
| Q3 25 | 3.5% | 64.4% | ||
| Q2 25 | 4.7% | 67.7% | ||
| Q1 25 | 1.2% | 63.6% | ||
| Q4 24 | 13.2% | 65.9% | ||
| Q3 24 | -82.8% | 61.3% | ||
| Q2 24 | 15.9% | 58.6% |
净利率PCRXRGLD
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 24.9% | ||
| Q3 25 | 3.0% | 50.3% | ||
| Q2 25 | -2.7% | 63.1% | ||
| Q1 25 | 2.8% | 58.7% | ||
| Q4 24 | — | 53.0% | ||
| Q3 24 | -85.1% | 49.7% | ||
| Q2 24 | 10.6% | 46.6% |
每股收益（稀释后）PCRXRGLD
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $1.04 | ||
| Q3 25 | $0.12 | $1.92 | ||
| Q2 25 | $-0.11 | $2.01 | ||
| Q1 25 | $0.10 | $1.72 | ||
| Q4 24 | $0.38 | $1.63 | ||
| Q3 24 | $-3.11 | $1.46 | ||
| Q2 24 | $0.39 | $1.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $233.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $7.2B |
| 总资产 | $1.2B | $9.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXRGLD
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $233.7M | ||
| Q3 25 | $246.3M | $172.8M | ||
| Q2 25 | $445.9M | $248.2M | ||
| Q1 25 | $493.6M | $240.8M | ||
| Q4 24 | $484.6M | $195.5M | ||
| Q3 24 | $453.8M | $127.9M | ||
| Q2 24 | $404.2M | $74.2M |
总债务PCRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $50.0M |
股东权益PCRXRGLD
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $7.2B | ||
| Q3 25 | $727.2M | $3.4B | ||
| Q2 25 | $757.8M | $3.3B | ||
| Q1 25 | $798.5M | $3.2B | ||
| Q4 24 | $778.3M | $3.1B | ||
| Q3 24 | $749.6M | $3.0B | ||
| Q2 24 | $879.3M | $3.0B |
总资产PCRXRGLD
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $9.5B | ||
| Q3 25 | $1.3B | $4.5B | ||
| Q2 25 | $1.5B | $3.6B | ||
| Q1 25 | $1.6B | $3.5B | ||
| Q4 24 | $1.6B | $3.4B | ||
| Q3 24 | $1.5B | $3.3B | ||
| Q2 24 | $1.6B | $3.3B |
负债/权益比PCRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $241.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 2.58× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PCRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $241.7M | ||
| Q3 25 | $60.8M | $174.0M | ||
| Q2 25 | $12.0M | $152.8M | ||
| Q1 25 | $35.5M | $136.4M | ||
| Q4 24 | $33.1M | $141.1M | ||
| Q3 24 | $53.9M | $136.7M | ||
| Q2 24 | $53.2M | $113.5M |
自由现金流PCRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | — | ||
| Q3 25 | $57.0M | — | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $26.9M | — | ||
| Q4 24 | $31.0M | — | ||
| Q3 24 | $49.8M | — | ||
| Q2 24 | $51.6M | — |
自由现金流率PCRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | — | ||
| Q3 25 | 31.7% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 15.9% | — | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 29.0% | — |
资本支出强度PCRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 0.9% | — |
现金转化率PCRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | — | 2.58× | ||
| Q3 25 | 11.20× | 1.37× | ||
| Q2 25 | — | 1.15× | ||
| Q1 25 | 7.37× | 1.20× | ||
| Q4 24 | — | 1.31× | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | 2.82× | 1.40× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
